Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in … Read more
Shanghai Medicilon Inc (688202) - Net Assets
Latest net assets as of June 2025: CN¥2.08 Billion CNY
Based on the latest financial reports, Shanghai Medicilon Inc (688202) has net assets worth CN¥2.08 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.83 Billion) and total liabilities (CN¥749.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.08 Billion |
| % of Total Assets | 73.55% |
| Annual Growth Rate | 31.04% |
| 5-Year Change | 88.45% |
| 10-Year Change | N/A |
| Growth Volatility | 58.71 |
Shanghai Medicilon Inc - Net Assets Trend (2016–2024)
This chart illustrates how Shanghai Medicilon Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Medicilon Inc (2016–2024)
The table below shows the annual net assets of Shanghai Medicilon Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.14 Billion | -14.76% |
| 2023-12-31 | CN¥2.51 Billion | +56.65% |
| 2022-12-31 | CN¥1.60 Billion | +20.74% |
| 2021-12-31 | CN¥1.33 Billion | +16.89% |
| 2020-12-31 | CN¥1.14 Billion | +13.50% |
| 2019-12-31 | CN¥1.00 Billion | +187.62% |
| 2018-12-31 | CN¥347.89 Million | +21.08% |
| 2017-12-31 | CN¥287.32 Million | +16.75% |
| 2016-12-31 | CN¥246.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Medicilon Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5567.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥359.54 Million | 16.80% |
| Other Components | CN¥1.78 Billion | 83.20% |
| Total Equity | CN¥2.14 Billion | 100.00% |
Shanghai Medicilon Inc Competitors by Market Cap
The table below lists competitors of Shanghai Medicilon Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Heritage Commerce Corp
NASDAQ:HTBK
|
$730.72 Million |
|
Beijing Haitian Ruisheng Science Technology Ltd
SHG:688787
|
$730.72 Million |
|
Harbin Electric Coporation Jiamusi Electric Machine Co Ltd
SHE:000922
|
$731.00 Million |
|
Synsam AB
ST:SYNSAM
|
$731.69 Million |
|
Matthews International Corporation
NASDAQ:MATW
|
$730.27 Million |
|
OVS S.p.A.
LSE:0R5R
|
$729.84 Million |
|
EYEPOINT PHARMAC. DL-01
F:PV3B
|
$729.65 Million |
|
Jiangsu Shuangxing Color Plastic New Materials Co Ltd
SHE:002585
|
$729.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Medicilon Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,510,779,364 to 2,140,157,223, a change of -370,622,141 (-14.8%).
- Net loss of 330,845,822 reduced equity.
- Dividend payments of 6,974,697 reduced retained earnings.
- Other factors decreased equity by 32,801,622.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-330.85 Million | -15.46% |
| Dividends Paid | CN¥6.97 Million | -0.33% |
| Other Changes | CN¥-32.80 Million | -1.53% |
| Total Change | CN¥- | -14.76% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Medicilon Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.64x to 4.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥6.10 | CN¥64.84 | x |
| 2018-12-31 | CN¥7.36 | CN¥64.84 | x |
| 2019-12-31 | CN¥16.02 | CN¥64.84 | x |
| 2020-12-31 | CN¥18.12 | CN¥64.84 | x |
| 2021-12-31 | CN¥21.38 | CN¥64.84 | x |
| 2022-12-31 | CN¥18.42 | CN¥64.84 | x |
| 2023-12-31 | CN¥18.64 | CN¥64.84 | x |
| 2024-12-31 | CN¥15.89 | CN¥64.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Medicilon Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.88%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.32x
- Recent ROE (-15.46%) is below the historical average (10.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 17.85% | 18.68% | 0.67x | 1.42x | CN¥19.08 Million |
| 2017 | 14.69% | 16.70% | 0.64x | 1.37x | CN¥13.28 Million |
| 2018 | 17.75% | 18.70% | 0.69x | 1.38x | CN¥26.53 Million |
| 2019 | 6.70% | 14.81% | 0.40x | 1.14x | CN¥-32.73 Million |
| 2020 | 11.52% | 19.43% | 0.49x | 1.21x | CN¥17.06 Million |
| 2021 | 21.26% | 24.18% | 0.65x | 1.35x | CN¥149.47 Million |
| 2022 | 21.10% | 20.39% | 0.71x | 1.45x | CN¥177.96 Million |
| 2023 | -1.32% | -2.43% | 0.42x | 1.30x | CN¥-284.29 Million |
| 2024 | -15.46% | -31.88% | 0.37x | 1.32x | CN¥-544.86 Million |
Industry Comparison
This section compares Shanghai Medicilon Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Medicilon Inc (688202) | CN¥2.08 Billion | 17.85% | 0.36x | $730.34 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |